Investigating the genetic factors that drive neuroendocrine cancers
Official title: Convergent Epigenetic Control of Neuroendocrine Cancers
Funded at Dana-Farber Cancer Inst · NIH-11016327 · Data updated 2026-11-12
This study is looking at the genes and other factors that might cause neuroendocrine cancers, like small intestinal tumors and neuroendocrine prostate cancer, to help find new ways to treat these cancers better for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $2,452,400 |
| NIH project number | 1P01CA295524-01 |
| Project ID | NIH-11016327 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals diagnosed with neuroendocrine cancers such as small intestinal neuroendocrine tumors, neuroendocrine prostate cancer, small cell lung cancer, or Merkel cell carcinoma.
✕Less likely to help
Patients with non-neuroendocrine cancers or those without a cancer diagnosis may not receive any benefit from this research.
What this research studies
This research focuses on understanding the genetic and epigenetic factors that contribute to the development of neuroendocrine cancers, which include various tumor types such as small intestinal neuroendocrine tumors and neuroendocrine prostate cancer. By examining these cancers across different tissue types, the research aims to identify common transcription factors and epigenetic regulators that influence cancer growth and behavior. The study will utilize advanced techniques like ATAC sequencing to analyze chromatin accessibility, helping to uncover vulnerabilities in cancer cells that could be targeted for new therapies. Patients may benefit from insights that could lead to improved treatment strategies tailored to their specific cancer type.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapeutic targets for treating neuroendocrine cancers.
How similar studies have gone: Previous research has shown promising results in understanding the genetic underpinnings of neuroendocrine tumors, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Decaprio, James a. — Dana-Farber Cancer Inst
- Study coordinator: Decaprio, James a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.